![](/images/graphics-bg.png)
Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
المؤلفون المشاركون
Wang, Han
Zhang, Qingyuan
Lu, Lu
Li, Zhenzhi
Xu, Lei
Li, Xiaojiao
المصدر
Saudi Journal of Biological Sciences
العدد
المجلد 25، العدد 5 (31 يوليو/تموز 2018)، ص ص. 909-916، 8ص.
الناشر
تاريخ النشر
2018-07-31
دولة النشر
السعودية
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
The goal of this study was to assess the antitumor efficacy and safety of lobaplatin-based regimens as the second line of treatment in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes, compared with that of cisplatin-based regimens.
During August 2012 to April 2015, 87 patients who received lobaplatin-based regimens or cisplatin-based regimens were included.
Medical records of the patients noted that lobaplatin (30 mg/m2) or cisplatin (25 mg/m2), combined with another chemotherapeutic agent such as Gemcitabine (1000 mg/m2) or Vinorelbine (25 mg/m2), was intravenously given to the patients on a basis of twenty-one days as one treatment cycle.
All the patients were followed until August 2017.
The endpoint of this study was progression-free survival (PFS), overall survival (OS), and estimated objective response rate (RR).
Safety and drug tolerability data were also obtained.
Lobaplatin-based regimens prolonged PFS compared to cisplatin-based regimens (median 13.2 vs 4.7 months, hazard ratio = 0.37, 95% confidence intervals: 0.21–0.67, P = .0007), while OS was not significantly different between the two groups (hazard ratio = 0.72, 95% confidence intervals: 0.40–1.30, P = .2767), as was objective RR (37.8% vs 33.4%, x2 = 0.19, P = .6653).
Nausea/vomiting and renal injury were more frequent with cisplatin-based regimens.
Our results show that lobaplatinbased regimens are superior to cisplatin in terms of efficacy and are better tolerated.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Xu, Lei& Wang, Han& Li, Zhenzhi& Lu, Lu& Li, Xiaojiao& Zhang, Qingyuan…[et al.]. 2018. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi Journal of Biological Sciences،Vol. 25, no. 5, pp.909-916.
https://search.emarefa.net/detail/BIM-838768
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Xu, Lei…[et al.]. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi Journal of Biological Sciences Vol. 25, no. 5 (Jul. 2018), pp.909-916.
https://search.emarefa.net/detail/BIM-838768
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Xu, Lei& Wang, Han& Li, Zhenzhi& Lu, Lu& Li, Xiaojiao& Zhang, Qingyuan…[et al.]. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi Journal of Biological Sciences. 2018. Vol. 25, no. 5, pp.909-916.
https://search.emarefa.net/detail/BIM-838768
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 915-916
رقم السجل
BIM-838768
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)